Answers are grounded in this paper and cite their sources.
The recently-published first head-to-head study comparing the efficacy of two biological drugs on monotherapy, tocilizumab and adalimumab, found better results for tocilizumab. Both are cytokine-specific antagonists: adalimumab targets tumor necrosis factor and tocilizumab targets interleukin-6 receptor . The aim of our review was to determine differences in the mechanisms of action of adalimumab and tocilizumab, in order to explain the differing results found, and to describe the immunologic and clinical aspects of the two drugs.
No takes yet. Share an insight, caveat, or question.
Silvia Vidal Raimon Sanmarti (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: